Radiopharmaceutical Therapy - Xofigo

Radium 223 Dichloride is the generic name for Xofigo. Xofigo is a alpha particle-emitting radioactive therapeutic agent. 

​

Xofigo (Ra223) is a type of internal radiotherapy treatment for cancer that began in prostate and has spread to the bones.

​

Xofigo is suitable for metastatic castrate-resistant prostate cancer mCRPC patients on second-generation hormonal therapy that has bone metastases, and no visceral metastases, and a suspected disease progression such as increase in biomarker levels or emerging symptoms (use of analgesics).

​

Xofigo extends the median overall survival to 14.9 months. Xofigo can be used after chemotherapy, with no known drug-drug interaction and can be administered without steriods or needing to fast.

Treatment can be completed in 5 months with 6 injections in total, where you can return home after the injection.